Business Development

As a fast growing and profitable European Speciality pharmaceutical company IS Pharma has a forward thinking and active Business Development culture.
With a dedicated Business Development team and a proven track record IS Pharma can offer a rapid, flexible approach to deal making and commercialisation of products across Europe. 

Licensing in

IS Pharma is actively seeking acquisition, distribution or in-licensing opportunities for late stage and commercialised hospital specialist pharmaceuticals and devices. We are interested in obtaining European rights to opportunities to complement and build our portfolio particularly in the areas of:

Oncology

Critical Care

Neurology

 IS Pharma welcomes enquiries from companies looking for the right partner to commercialise their asset to its full potential.

Licensing out

IS Pharma has a number of opportunities in its product and development portfolio for partners who are looking for their next opportunity. We would be pleased to receive enquiries on the opportunities below:

Haemopressin/Variquel
IS Pharma has global rights for Haemopressin/Variquel and is looking to expand its network of partners outside of Europe.

episil
IS Pharma has the rights for the EU for Episil and is looking for partners to commercialise this exciting opportunity in a number of the EU countries.

Micelle nanotechnology
IS Pharma’s micelle nanotechnology solubilises insoluble active pharmaceuticals and is subject to a number of granted and pending patent applications. We welcome enquiries from companies interested in developing and commercialising products using the technology.  

For more information on in-licensing and out-licensing please contact:

Nairn McMaster

Commercial Director

Email: bd@ispharma.plc.uk
Tel: 01244 625150              01244 625150      
Fax: 01244 625151